西班牙机构提供口服抗凝血药在血液中的快速免疫测定

两家西班牙的研究机构开发了一种免疫测定方式，能够对口服抗凝血药进行量化测定来阻止血栓疾病，同时能够延长前凝血酶时间，帮助更好的检测病患。该机构希望与能将此技术市场化的合作伙伴进行许可证协议合作。

Details:

About 2% of population is under treatment with oral coumarin anticoagulants (OAs), such as warfarin or acenocoumarol. The main problems associated to these drugs are their narrow therapeutic window and their unpredictable dose-response relationship. Thus, there is a large inter and intraindividual variability, but also bioavailability is affected by factors such as age, diet, medications, etc, requiring a personalized adjust and correction of the dose along the treatment.

Current methods to adjust OAs dose are based on the determination of the prothrombin time (PT) expressed as the International Normalized Ratio (INR). Nevertheless, in many cases ideal INR, based only in pharmacodynamic facts is difficult to achieve, and complementarily, measurement of plasma concentrations of the OAs should be taken into account.

A new ELISA-test able to quantify plasmatic levels of acenocoumarol and warfarin is presented. This method is rapid, sensitive, allows routine monitoring and individual pharmacokinetic studies of these drugs, in contrast to other methods based on HPLC or GC-MS.

The immunoreagents produced do show high avidity for the coumarin OAs and could be used on different immunochemical analytical configurations, including ELISA microplates, test strips, immunosensors or any other format suitable for further implementation on Point-of-Care (PoC) devices.

In combination with the measurement of PT, this test could provide a complete profile of the drug level for better monitoring of the patient and their response to medication.

Type and Role of Partners Sought:

Pharma or biotech companies interested in diagnostics

Activity of the partner: diagnosis, blood coagulation

联系人：荣皓

电话：028-85336986

手机：13880491154

邮箱：bright_rong@eupic.org.cn